玻璃体腔注射抗血管内皮生长因子单克隆抗体bevacizumab后视功能的变化被引量：1

导出

摘要玻璃体腔注射抗血管内皮生长因子单克隆抗体bevacizumab（商品名：Avastin）后,患眼功能改善或稳定,疗效和安全性良好.其中,视功能变化表现为视力显著提高,对比敏感度稳定不变或明显改善,视网膜电图（ERG）未出现显著改变,多焦视网膜电图（mfERG）反应稳定或改善,眼电图（EOG）和视觉诱发电位（VEP）与治疗前相比无明显改变,视野保持稳定或轻微改善,色觉保持不变.但重复注射、bevacizumab联合其它治疗后的视功能变化以及长期疗效及安全性仍需更加充分的评估依据进行大样本长时间随访研究.

作者李菲陈长征

机构地区武汉大学人民医院眼科

出处《中华眼底病杂志》 CAS CSCD 北大核心 2011年第1期97-99,共3页 Chinese Journal of Ocular Fundus Diseases

关键词血管内皮生长因子类抗体单克隆/治疗应用综述文献

分类号 R774.1 [医药卫生—眼科]

引文网络
相关文献

参考文献35

1Miki K,Miki A,Matsuoka M,et al.Effects of intraocular ranibizumab and bevacizumab in transgenic mice expressing human vascular endothelial growth factor.Ophthalmology,2009,116:1748-1754.
2Nicholson BP,Schachat AP.A review of clinical trials of antiVEGF agents for diabetic retinopathy.Graefes Arch Clin Exp Opht halmol,2010,248:915-930.
3Rich RM,Rosenfeld PJ,Puliafito CA,et al.Short term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age related macular degeneration.Retina,2006,26:495 511.
4Scupola A,Tiberti AC,Sasso P,et al.Macular functional changes evaluated with MP-1 microperimetry after intravitreal bevacizumab for subfoveal myopic choroidal neovascularization:one-year results.Retina,2010,30:739 747.
5唐仕波,梁小玲,胡洁,丁小燕,万婷,郭梦翔,胡忆群.玻璃体腔注射bevacizumab治疗年龄相关性黄斑变性的初步临床观察[J].中华眼科杂志,2007,43(10):890-896. 被引量：13
6Avery RL,Pearlman J,Pieramici DJ,et al.Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy.Ophthalmology,2006,113:1695-1705.
7Yoganathan P,Deramo VA,Lai JC,et al.Visual improvement following intravitreal bevacizumab (Avastin) in exudative agerelated macular degeneration.Retina,2006,26:994-998.
8Gharbiya M,Allievi F,Recupero V,et al.Intravitreal bevacizumab as primary treatment for retinal angiomatous proliferation:twelve-month results.Retina,2009,29:740-749.
9Cervantes-Castaneda RA,Giuliari GP,Gallagher MJ,et al.Intravitreal bevacizumab in refractory uveitic macular edema:one-year follow-up.Eur J Ophthalmol,2009,19:622-629.
10Michels S,Rosenfeld PJ,Puliafito CA,et al.Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration.Twelve-week results of an uncontrolled open-label clinical study.Ophthalmology,2005,112:1035-1047.

二级参考文献8

1Campochiaro PA. Retinal and choroidal neovascularization. J Cell Physiol, 2000,184 : 301-310.
2Krzystolik MG, Afshari MA, Adamis AP, et al. Prevention of experimental choroidal neovascularization with intravitreal antivascular endothelial growth factor antibody fragment. Arch Ophthalmol, 2002,120:338-346.
3Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med, 2004,350:2335-2342.
4Wang Y, Fei D, Vanderlaan M, et al. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis, 2004, 7: 335-345.
5Tolentino MJ, Husain D, Theodosiadis P, et al. Angiography of fluoresceinated anti-vascular endothelial growth factor antibody and dextrans in experimental choroidal neovascularization. Arch Ophthalmol, 2000,118:78-84.
6Michels S, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration :twelve-week results of an uncontrolled openlabel clinical study. Ophthalmology, 2005,112 : 1035-1047.
7D'Orazio A, Lee D, Ellis L, et al. Adding a humanized antibody to vascular endothelial growth factor ( bevacizumab, Avastin) to chemotherapy improves survival in metastatic colorectal cancer. Clin Colorectal Cancer, 2003, 8:85-88.
8Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase Ⅱ, randomized trial comparing bevacizumab plus fluorouracil( FU)/ leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol, 2003, 21:60-65.